AAF IS LOOKING AT THE US MARKETS
Altachem Pharma Ltd. Signs Madison Keats(TM) to Assess Potential Business and Financing Strategies in the U.S.
2/26/03
EDMONTON, ALBERTA, Feb 26, 2003 (CCNMatthews via COMTEX) --
Mr. Doug Bachman, Vice President of Corporate Development of Altachem Pharma Ltd. is pleased to announce that Altachem is working with the investment banking firm of Madison Keats to assist in evaluating potential business and financing strategies in the U.S. Mr. Bachman states, "We look forward to working with a significant member of the life sciences market in the United States."
"Madison Keats specializes in the life sciences area and understands the value of Altachem's business model and technology portfolio," states Mr. James Sarene, Managing Director of Madison Keats. Mr. Sarene also states, "Madison Keats builds and maintains alliances with an exclusive clientele that includes several multinational pharmaceutical companies." "Working with a significant firm in the U.S. life sciences market will increase exposure and assist in maximizing corporate value," states Mr. Bachman.
Madison Keats works exclusively within the life sciences industry. Headquartered in Charlotte, North Carolina, the firm is strategically situated in the second largest banking center in the U.S. and within close proximity to Research Triangle Park in North Carolina.
Altachem Pharma Ltd. is a publicly traded (TSX Venture Exchange: AAF), Alberta-based pharmaceutical company committed to the development and commercialization of new pharmaceutical products. The Corporation is developing a multi-tiered, integrated approach for the treatment of HIV/AIDS and cancer using non-toxic therapeutic products and adjunct therapies. The lead products of the Corporation are based on its two proprietary drugs: ACP-HIP and HB. The Corporation's manufacturing facilities located in Edmonton, Alberta and Shanghai, China are certified compliant with internationally recognized quality systems standards.
Certain information contained in this press release may be forward-looking and is subject to unknown risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct. This is neither an offer to buy or sell a security. For informational purposes only, from sources deemed to be reliable.
Altachem Pharma Ltd.
Roger Andrews
Investor Relations
(780) 486-8331 (Ext. 331) or Toll Free: 1-877-502-5939
(780) 448-1436 (FAX)
Email: roger@altachempharma.com
Website: www.altachempharma.com
or
Renmark Financial Communications Inc.
Barry Mire
(514) 939-3989
(514) 939-3717 (FAX)
Email: bmire@renmarkfinancial.com
Website: www.renmarkfinancial.com
or
Renmark Financial Communications Inc.
Dominic Sicotte
Media
(514) 939-3989
(514) 939-3717 (FAX)
Email: dsicotte@renmarkfinancial.com
NEWS RELEASE TRANSMITTED BY CCNMatthews TSX Venture Exchange has neither approved nor disapproved of the information contained herein.
Copyright (C) 2003, CCNMatthews. All rights reserved. |
